Gum Chewing Helps Prevent Intestinal Blockages In Patients With Cancer After Abdominal Surgery

Article

According to a study presented at 2017 ONS Annual Congress by nurses at University of Texas Southwestern Medical Center, gum chewing may be able to prevent post-operative ileus (intestinal blockages) in patients with cancer who have undergone abdominal surgery.

Intestinal blockages after abdominal surgery in patients with cancer — known as post-operative ileus (POI) — are common enough to require between $750 million and $1.5 billion in treatment every year in the United States.

Between 3 and 32 percent of patients in this population experience POI, which is caused by decreased gut motility, and one episode can cost up to $15,000 to treat, according to the lead author of a pilot study on the issue that was presented during the 42nd Annual Congress of the Oncology Nursing Society.

That’s not to mention what the authors described as “immeasurable pain and suffering for patients.”

But what if there was a simple, noninvasive and inexpensive way to prevent POI in some patients? The pilot study conducted at UT Southwestern Medical Center, in Dallas, Texas, suggests that there is, and that oncology nurses are best positioned to administer it: chewing gum.

The study’s authors — Linda Chan, B.S.N., RN, OCN, Melissa Trevino, BBA, ADN, RN, OCN, and Sharon LeRoux, B.S.N., RN, CMSRN, OCN — moved forward with their project based on the strength of previous research that found evidence to support the measure. A 2015 meta-analysis of 81 studies and 9,072 patients found that gum chewing had decreased the time to first flatus by 10.4 hours, the time to first bowel movement by 12.7 hours and the length of hospital stay by 0.7 days, Chan reported at ONS.

Researchers have found a couple of reasons for the effectiveness of gum chewing in these patients, Chan said: It stimulates the vagus nerve that enervates the gut, and it produces saliva, which causes the gut to secrete gastric hormones. She added that studies show that sugar-free gum may be preferable in preventing POI. “The sweetening agents used in sugar-free gums are sorbitol or mannitol, which creates an osmotic effect, or diarrhea,” she said.

In the pilot study in a 32-bed surgical oncology unit, the three nurses considered how gum chewing versus no gum chewing affected POI status in patients with cancer hospitalized after abdominal surgery.

When patients underwent abdominal surgery, nurses worked with attending physicians to add a “may chew gum” order to their charts, when appropriate. Regardless of their prescribed diet, patients were free to participate unless they were disoriented or otherwise unsafe to chew gum. Doctors’ medical orders were coupled with patient education in the form of packets explaining POI and that gum chewing might prevent it. Participation was voluntary, with nurses supplying regular or sugar-free gum to those who opted into the program. Gum chewing status was recorded in patients’ electronic health records.

Patients were advised to start chewing gum six hours after surgery or when fully awake, four times a day and as desired. Nurses offered gum when patients were alert, oriented and safe to chew it, and stopped offering it as of each patient’s first bowel movement after surgery. Nurses monitored patients’ gum-chewing status and communicated about it in between-shift huddles and in bedside reports, and on hospital-room white boards. Gut motility was measured via X-ray.

From April 1 through August 31, 2016, 159 patients on the unit underwent abdominal surgery; 74 of them chewed gum and 85 did not. A total of 15 of the patients developed POI. Five of them, or 6.8 percent of the overall group, had chewed gum. Ten of them, or 11.8 percent, had not.

“Gum chewing is a low-cost intervention with little risk for alert, oriented, recovering abdominal surgical oncology patients who safely chew and swallow,” the authors wrote in their abstract. “This model is replicable in other surgical units.” They added that preventing just one incidence of POI would make the intervention worthwhile.

The nurses plan to follow up on these results by conducting a retrospective study comparing current POI rates in this population of patients with those recorded before the unit’s practice change in favor of gum chewing.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.